{
    "nct_id": "NCT03951077",
    "official_title": "Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome",
    "inclusion_criteria": "* Participants with clinical diagnosis of PCOS.\n* Participants with a body mass index (BMI) of 18.5 to 38 kg/m^2 at time of Screening.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 35 Years",
    "exclusion_criteria": "* Participants with newly diagnosed medical condition requiring intervention that has not been stabilized at least 30 days prior to Baseline.\n* Participants with a significant medical condition that require intervention during the course of study participation (such as anticipated major elective surgery).\n* Participants with an unstable medical condition (including, but not limited to, uncontrolled hypertension, epilepsy requiring anti-epileptic medicine, unstable angina, confirmed inflammatory bowel disease, hyperprolactinemia, clinically significant infection or injury).",
    "miscellaneous_criteria": ""
}